Shots:
- VERAXA Biotech has entered into a co-discovery alliance with OmniAb to develop novel bispecific antibody drug conjugate (bsADC) targeting solid tumors using the former’s ADC linker tech & conjugation expertise & OmniAb’s suite of transgenic antibody discovery solutions
- As per the deal, VERAXA will initiate novel bsADC program targeting 2 cancer-related molecules, using OmniAb’s transgenic antibody platform to identify leads, & applying its linker & conjugation tech to establish bsADC lead candidate
- VERAXA will handle preclinical validation & co-own the resultant bsADC program while sharing future revenues from development, licensing, & commercialization with OmniAb
Ref: Globenewswire | Image: VERAXA Biotech & OmniAb
Related News:- VERAXA Biotech Enters a Business Combination Agreement with Voyager Acquisition Corp to Develop Cancer Therapies
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click Here for the Full Press Release
